Merck and Moderna's mRNA melanoma vaccine cuts recurrence risk by 60%

Merck and Moderna have announced successful late-stage trial results for an mRNA melanoma vaccine. Combined with standard immunotherapy, the vaccine reduces the risk of recurrence and distant metastasis by 60% compared to immunotherapy alone. Experts at Penn Medicine and the American Association for Cancer Research described the results as a breakthrough.